Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2023-06-01 00:00:00 ET · period of report 2023-05-31 · accession 0001628280-23-020508 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-06-01 | 2023-05-31 | NAGE | Fried Robert N | CEO, Dir | P - Purchase | $1.42 | +7,000 | 95.0K | +8% | +$9,940 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | P | A | 7,000 | $1.42 | 95,001 | I By Fried-Travis Revocable Trust U/A Dated 06/02/1999 | — | — |